Publications:

CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis.

Frontiers In Pharmacology

Hisert, Katherine B KB; Birkland, Timothy P TP; Schoenfelt, Kelly Q KQ; Long, Matthew E ME; Grogan, Brenda B; Carter, Suzanne S; Liles, W Conrad WC; McKone, Edward F EF; Becker, Lev L; Manicone, Anne M AM; Gharib, Sina A SA

Publication Date: 2020

Variant appearance in text: CFTR: M156R

PubMed Link: 33013356

Variant Present in the following documents:

• Main text
• fphar-11-01219.pdf

View BVdb publication page

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations.

The European Respiratory Journal

Hardisty, Gareth R GR; Law, Sheonagh M SM; Carter, Suzanne S; Grogan, Brenda B; Singh, Pradeep K PK; McKone, Edward F EF; Gray, Robert D RD

Publication Date: 2021-01

Variant appearance in text: CFTR: M156R

PubMed Link: 32855222

Variant Present in the following documents:

• Main text
• ERJ-02161-2020.pdf

View BVdb publication page

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis.

Erj Open Research

Hisert, Katherine B KB; Birkland, Timothy P TP; Schoenfelt, Kelly Q KQ; Long, Matthew E ME; Grogan, Brenda B; Carter, Suzanne S; Liles, W Conrad WC; McKone, Edward F EF; Becker, Lev L; Manicone, Anne M AM

Publication Date: 2020-04

Variant appearance in text: CFTR: M156R

PubMed Link: 32337217

Variant Present in the following documents:

• Main text
• 00318-2019.pdf

View BVdb publication page